FDA Approves New Rx-to-OTC Switch for Allergy Nasal Spray
GSK Consumer Healthcare announced that the Food and Drug Administration (FDA) has approved Flonase Sensimist Allergy Relief (fluticasone furoate) spray, an over-the-counter (OTC) treatment for symptoms associated with seasonal and perennial allergies in patients aged ≥2 years.
Flonase Sensimist was previously available as a prescription product, under the name Veramyst. It provides non-drowsy, 24-hour relief of both nose- and eye-related allergy symptoms including itchy, watery eyes, nasal congestion, runny nose, itchy nose, and sneezing.
Flonase Sensimist contains fluticasone furoate, a synthetic corticosteroid with potent anti-inflammatory activity. Corticosteroids have been shown to have a wide range of actions on multiple cell types (eg, mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (eg, histamine, eicosanoids, leukotrienes, cytokines) involved in inflammation. The precise mechanism through which fluticasone furoate affects rhinitis symptoms is not known.
Flonase Sensimist is scent- and alcohol-free with little or no drip. It will be available as a 27.5mcg strength spray in early 2017.
For more information call (888) 825-5249 or visit us.gsk.com.